Prenatal detection of a 3q29 microdeletion in a fetus with ventricular septum defect
A case report and literature review

Fagui Yue, MMa,b, Shu Deng, MSc,b, Qi Xi, MSc,a,b, Yuting Jiang, MSc,a,b, Jing He, MSc,a,b, Hongguo Zhang, PhD:a,b, Ruizhi Liu, MD, PhD:a,b,*

Abstract
Rationale: Chromosomal 3q deletion is a recurrent genomic alteration, which is rarely reported in clinic.
Patient concerns: A 27-year-old woman underwent amniocentesis for cytogenetic analysis and single nucleotide polymorphism (SNP) array analysis at 27 weeks of gestation, due to ventricular septum defect in prenatal ultrasound findings.
Diagnoses: G-banding analysis showed the karyotype of the fetus was normal and the couple also had normal karyotypes. However, SNP array detected a 1.71 Mb microdeletion in 3q29, which was described as arr[hg19]3q29(194184392–195887205)×1. There are 12 genes located in this locus.
Interventions: The couple refused SNP array to testify the 3q29 microdeletion was inherited or de novo and they chose termination of pregnancy.
Outcomes: The deleted region in the fetus overlapped with part 3q29 microdeletion syndrome, which was characterized by learning disability, speech delay, mental deficiency, ocular abnormalities and craniofacial features. In addition, no similar/overlapping 3q29 microdeletion cases were reported according to the published literature and database.
Lessons: For the chromosomal microscopic imbalances partially overlapping with the defined pathogenic syndrome, deleted/duplicated size, genetic materials and phenotypic diversity should be taken into consideration when genetic counseling is offered by the clinicians.

Abbreviations: OMIM = online Mendelian inheritance in man, SNP = single nucleotide polymorphism.

Keywords: 3q29 microdeletion, genetic counseling, single nucleotide polymorphism array, ventricular septum defect

1. Introduction
Chromosomal microscopic imbalances, microdeletions/microduplications, are associated with multiple genetic disorders, including intellectual disability (ID), developmental delay, autistic spectrum disorders (ASD) and congenital abnormalities. For submicroscopic copy number variations (CNVs) which are too small to be detected by banding technique, chromosomal microarray analysis (CMA) allows the detection of these chromosomal aberrations associated with well-described phenotypes. With the extensive application of high-resolution microarrays, a large number of microdeletions and microduplications syndromes have been described in recent years, with 22q11.2, 7q11.23, 17p11.2 and 16p11.2 most common in clinic. Meanwhile, pathogenic CNVs, due to deletions or duplications, may lead to variable expressivity among individuals.

Terminal deletion of 3q, mostly de novo, was a recurrent genomic alteration which was first reported in 2001. The incidence rate of 3q29 deletion was approximately 1/30,000-40,000. Till now, more than 40 cases involving submicroscopic 3q29 deletion have been reported in published literature. The clinical manifestations were variable and characterized by learning disability, mental deficiency, speech delay, ocular abnormalities and craniofacial features, such as high nasal bridge and microcephaly. In addition, autism, heart defects, hypospadias and gastrointestinal abnormalities were also observed in some cases. Generally speaking, there might exist phenotypic diversity in patients with 3q29 microdeletion.

In prenatal cases with normal karyotypes, the detection rate of chromosomal microdeletion/microduplication was approximately 1% of pregnancies without structural abnormalities and 6% with structural abnormalities. Herein, we report a fetus with a
1.7 Mb microdeletion in chromosome 3q29, accompanied with abnormal prenatal ultrasound findings. We have also provided a literature review on cases with similar 3q29 microdelered locus involving cardiac defect phenotypes.

2. Methods

The study protocol was approved by the Ethics Committee of the First Hospital of Jilin University (No.2017–441), and written informed consent was obtained from the couple for publication of this case report and accompanying images.

2.1. Cytogenetic analysis

Amniocentesis was performed for karyotyping analysis with informed consent. The sample was collected from amniotic fluid cells, and was cultured by standard operating procedure. Cultured peripheral blood cells of the couple were also obtained for karyotyping. Cytogenetic analysis was performed by G-banding technique in 20 metaphases for all samples, with a resolution of 300–400 bands. Chromosomal karyotypes were described based upon the International System for Human Cytogenetic Nomenclature.[10]

2.2. Single nucleotide polymorphism (SNP) array

SNP array analysis was carried out using the Human CytoSNP-12 DNA Analysis BeadChip (Illumina, San Diego, CA). Genomic DNA was extracted from 10mL uncultured amniotic fluid cells using QIAamp DNA Mini kit (Qiagen, Hilden, Germany). Data was analyzed by Illumina’s Genome Studio software. The final results were analyzed using Database of Chromosomal Imbalance and Phenotype in Humans using Ensemble Resources, Database of Genomic Variants, Online Mendelian Inheritance in Man (OMIM) and the National Center for Biotechnology Information.[10]

3. Case presentation

A 27-year-old, gravida 2, para 0, woman accepted amniocentesis for cytogenetic and SNP array analysis at 27-week gestation due to 27 weeks’ sonography findings inferring ventricular septum defect (VSD) at the Center for Reproductive Medicine and Center for Prenatal Diagnosis. The wife and her husband were nonconsanguineous and healthy. There was no family history of diabetes mellitus or congenital malformations. The mother denied any exposure to alcohol, teratogenic agents, irradiation, or infectious diseases during this pregnancy.

The fetus presented ventricular septum defect in ultrasound examination. G-banding analysis described the chromosomal karyotype of fetus as normal. However, SNP analysis identified a 1.71 Mb deletion in 3q29; arr[hg19]3q29 (194184392–195887205) ×1 (Fig. 1), overlapping with part 3q29 microdeletion syndrome. In our case, 12 genes are located in this deleted region, including ATP13A1, TMEM44, LSG1, FAM43A, XXYLT1, ACP2, PPP1R2, APOD, MUC20, MUC4, TNK2 and TFRC (Fig. 2). Chromosomal karyotypic analysis showed that the couple presented normal karyotypes. The couple refused to accept SNP analysis to identify the 3q29 microdeletion in the fetus was de novo or parentally inherited. According to genetic counseling, the couple finally chose to terminate the pregnancy based upon abnormal SNP results and ultrasound abnormalities.

4. Discussion

In our study, we delineated a rare prenatal case presenting VSD in ultrasound findings, who carried a 1.71 Mb deletion in the region of 3q29 (chr3: 194184392–195887205, hg19) using cytogenetic and molecular cytogenetic techniques. To the best of our knowledge, no similar 3q29 microdeletion cases in published literature and databases were reported before.

The 3q29 microdeletions are rare recurrent CNVs, most of which are de novo.[16] This syndrome is associated with a wide range of clinical features among the individuals, mainly characterized by intellectual disability, development delay, language retardation, craniofacial abnormalities, musculoskeletal abnormalities, autism, and congenital heart defect. According to the clinic observation, patients with this subchromosomal deletion in the terminal of 3q are usually discovered based upon clinical findings in childhood, with typically heterozygous 1.6 Mb deletion.[11]

Till now, cases with 3q29 microdeletion are rarely reported in clinic.[8–12] Considering the unusual cardiac defect discovered in such cases, we reviewed the literature and made a comparison on 3q29 microdeletion cases presenting cardiac anomalies to delineate the phenotype-karyotype correlations clearly (Table 1).[7,13–18] All 3q29 microdeletions varied in size, from 0.96 Mb to 1.6 Mb. The age of the cases ranged from 10 months to 13 years: 3/10 cases were de novo, 3/10 cases were parentally inherited, and this detail was not available in 4/10 cases. The clinical characteristics were as follows: congenital heart defect (9/10), development delay (6/10), mental retardation (6/10), craniofacial dysmorphic features (6/10), which were consistent with previous reports of 3q29 microdeletions. Diverse facial dysmorphisms could also be discovered in these cases: Ear anomalies (4/10), microcephaly (3/10), short pituitary (3/10), abnormal nasal bridge (2/10). In addition, gastroesophageal signs was observed in 2/10 cases. Based upon the observations above, a complex of other clinical abnormalities existed in these 3q29 microdeletion cases presenting with cardiac disease. The deleted locus in our case overlapped with part region of typical 3q29 duplication syndrome, which might be responsible for the abnormal ultrasonography to some extent. In addition, some rare anomalies involving neural and skeletal development have been reported in some cases. Guo et al.[12] described a 7-year-old girl with Chiari malformation type II and Sprengel’s deformity, accompanied by a novel 666kb microdeletion in 3q29 (chr3:194,532,035–195,198,585; hg19). Since the couple in our study did not accept SNP array, we fail to confirm the deletion was de novo or inherited. They made the decision to terminate the pregnancy, so we could not predict the postnatal growth conditions of the fetus in future. Hence irrespective of whether the 3q29 microdeletion is typical or atypical, more clinic data is required to establish a clear phenotype-karyotype correlation.

The canonical deletion region of 3q29 microdeletion syndrome almost ranges from 195.7 Mb to 197.3 Mb (Fig. 2), including more than 20 genes. Most reported 3q29 microdeletion cases included PAK2 and DLG1 genes, which are autosomal homologs of the X-linked genes PAK3 and DLG3. Haplosufficiency of PAK3 or DLG3 was reported to be associated with mental retardation.[16] Comparing our case with typical 3q29 microdeletion syndrome, our case presented an atypical 3q29 deletion with affected region ranging from 194.1 Mb to 195.8 Mb, consisting of 12 genes (Fig. 2).
TFRC (OMIM: 190010), as a morbid gene, encodes the transferrin receptor which is important and necessary for cellular iron, development of erythrocytes and the nervous system. It plays a critical role in intracellular iron transport. The mutation of TFRC was found to be associated with immunodeficiency 46 (OMIM: 616740).\textsuperscript{[7]} It could be abnormally overexpressed in epithelial ovarian cancer.\textsuperscript{[19]} Downregulation of TFRC is predictive of recurrent Major Depressive Disorder (MDD), which may indicate the role of the innate immune system in depression.\textsuperscript{[20]} XXYLT1 (OMIM: 614552), known as Xyloside α-1,3-xylosyltransferase, is a retaining Glycosyltransferase of the GT8 family. It can catalyze the addition of the second xylose to elongate the xylose-glucose disaccharide in the extracellular domain of Notch proteins. It was speculated that XXYLT1

Figure 1. SNP array on uncultured amniocytes depicted 3q29 deletion.
| References        | Chirita Emandi et al[7] | Citta et al[13] | Dasouki et al[14] | Digilio et al[16] | Li et al[16] | Ballif et al[17] | Monfort et al[18] | Patient 1 | Patient 3 | Patient 2 | Patient 3 | Patient 1 | Patient 1 father | Our case |
|-------------------|-------------------------|-----------------|-------------------|--------------------|--------------|-----------------|------------------|-----------|-----------|-----------|-----------|-----------|------------------|---------|
| Gender            | M                       | M               | F                 | F                  | M            | M               | F                | M         | M         | F         | F         | M         | Father          | Our case |
| Age               | 7 yr                    | 13 yr           | 8 yr              | 5 yr               | 10 mo        | 1.3–1.4         | 13.1–1.4         | 1.6       | 1.6       | 1.5       | 1.5       | 1.3       | 1.7              |         |
| Deletion size (Mb)| 0.96                    | NA              | 1.6              | 1.5                | 1.3          | 1.4             | 1.6              | 1.2       | 1.2       | 1.3       | 1.4       | 1.3       | 1.7              |         |
| Deletion range    | 195519657–196482211     | NA              | 197174369–198842531| (19577995–195786024) to (197310932–197310451) | NA           | 197199         | 19792774–198466778 | 194184392–195887205 |         |           |           |           |           |                  |         |
| Inheritance       | De novo                 | De novo         | De novo           | De novo            | De novo      | De novo         | Maternal         | Maternal | NA        |           |           |           |                  |         |
| Clinical features |                         |                 |                  |                    |              |                 |                  |           |           |           |           |           |                  |         |
| CHK               |                         |                 |                  |                    |              |                 |                  |           |           |           |           |           |                  |         |
| VSD               |                         | +               |                  |                    |              |                 |                  |           |           |           |           |           |                  |         |
| development delay |                         | +               |                  |                    |              |                 |                  |           |           |           |           |           |                  |         |
| mental retardation|                         | +               |                  |                    |              |                 |                  |           |           |           |           |           |                  |         |
| Craniofacial      |                         | +               |                  |                    |              |                 |                  |           |           |           |           |           |                  |         |
| dysmorphic        |                         | +               |                  |                    |              |                 |                  |           |           |           |           |           |                  |         |
| features          |                         | +               |                  |                    |              |                 |                  |           |           |           |           |           |                  |         |
| Microcephaly, full moon face, flattened facial profile, dental dysmorphic, large ears, auricular polyp | Microcephaly, short philtrum, high nasal bridge, large posteriorly rotated ears, long narrow face, ocular abnormality | Central incisions, bilateral epicanthal folds | Microcephaly, hanging nasal columella, short philtrum, thin upper lip | Related ears, frontal bossing, prominent nose, long thin lip, short palpebral fissures, single palmar creases | Rotated ears, frontal bossing, prominent nose, long thin lip, short palpebral fissures, single palmar creases | NA | NA | NA | NA | Micrognathia, low set ears, widened nasal bridge, short philtrum, hypertelorism | NA |
| Others            | NA                      | hypospadia, horseshoe kidney | GE reflux, urinary dysfunction | malpositioned toes | GE reflux | NA | NA | NA | NA | NA | NA | NA | NA |

+= feature present, - = feature absent, ASD = atrial septal defect, CHD = congenital heart defect, F = female, GE = gastroesophageal, M = male, NA = not available, PDA = patent ductus arteriosus, TOP = termination of pregnancy, VSD = ventricular septal defect.
dysfunction due to 3q29 microdeletion might impair epidermal growth factor (EGF) xylosylation, leading to up-regulated Notch signaling.[12,21] Human amplification of XXYLT1 in several kinds of cancer is frequently associated with decreased Notch signaling.[12] ACAP2 (OMIM: 607766), is an Arf-6 GTPase-activating protein which can inactivate Arf6 at the pericentrosomal endosomes and regulate neurite outgrowth.[11] In addition, the inactivation or downregulation of ACAP2 in human cells might contribute to cancer development.[21] ATP13A3 (OMIM: 610232), containing 18 exons, is a member of the P-type ATPase family of proteins. Its heterozygous mutation was associated with protein catalytic activity and the loss of ATP13A3 mRNA expression might inhibit proliferation and cause apoptosis promotion in endothelial cells.[24] Research on other genes involved are scarce. According to the ClinGen database, no supporting evidence of haploinsufficiency phenotypes for all 12 genes is available. Hence, further research is needed to define their implications and functions.

The utilization of chromosomal microarray analysis has facilitated the detection rate of subchromosomal imbalances, especially for prenatal cases with ultrasound anomalies. In order to avoid unnecessary abortions, the clinical significance of detected CNVs should be taken into account based upon deleted/duplicated size, genetic contents, inheritance pattern and clinical heterogeneity.[2]

5. Conclusions
In our study, we described a rare prenatal case with VSD, overlapping with part 3q29 microdeletion syndrome, which has not been reported before. For genetic disorders or syndromes of clinical significance, genetic counselling is offered. However, for chromosomal microscopic imbalances partially overlapping with the defined pathogenic syndrome, multiple factors, including deleted/duplicated size, genetic materials and phenotypic diversity, should be taken into consideration. As more similar 3q29 duplication cases and their associated phenotypes accumulate, it will help collect evidence on genotype-phenotype correlation of 3q29 microdeletion.

Author contributions
Conceptualization: Fagui Yue, Ruizhi Liu.
Data curation: Qi Xi, Yuting Jiang.
Formal analysis: Shu Deng, Jing He.
Funding acquisition: Fagui Yue, Ruizhi Liu.
Investigation: Qi Xi.
Methodology: Shu Deng, Hongguo Zhang.
Project administration: Ruizhi Liu.
Software: Yuting Jiang, Jing He.
Supervision: Hongguo Zhang.
Visualization: Hongguo Zhang.
Writing – original draft: Fagui Yue.
Writing – review and editing: Ruizhi Liu.

References
[1] Nevado J, Mergener R, Palomares-Bravo M, et al. New microdeletion and microduplication syndromes: a comprehensive review. Genet Mol Biol 2014;37:210–9.
[2] Levy B, Wagner R. Prenatal diagnosis by chromosomal microarray analysis. Fertil Steril 2018;109:201–12.
[3] Goldenberg P. An update on common chromosome microdeletion and microduplication syndromes. Pediatr Ann 2018;47:e198–203.
[4] Biamino E, Di Gregorio E, Belligni EF, et al. A novel 3q29 deletion associated with autism, intellectual disability, psychiatric disorders, and obesity. Am J Med Genet B Neuropsychiatr Genet 2016;171B:290–9.
[5] Rossi E, Piccini F, Zollino M, et al. Cryptic telomeric rearrangements in subjects with mental retardation associated with dysmorphism and congenital malformations. J Med Genet 2001;38:417–20.
[6] Glassford MR, Rosenfeld JA, Freedman AA, et al. Unique Rare Chromosome Disorder Support GroupNovel features of 3q29 deletion syndrome: results from the 3q29 registry. Am J Med Genet A 2016;170A:999–1006.
[7] Chirita Emandi A, Dobrescu AI, Doros G, et al. A novel 3q29 deletion in association with developmental delay and heart malformation-case report with literature review. Front Pediatr 2019;7:270.
[8] Khan WA, Cohen N, Scott SA, et al. Familial inheritance of the 3q29 microdeletion syndrome: case report and review. BMC Med Genomics 2019;12:51.
[9] Mcgowan-Jordan J, Simons A, Schmid M (eds)(2016) An international system for human cytogenomic nomenclature. S. Karger, Basel. [Reprint of Cytogenet Genome Res 149(1–2)].
[10] Yue F, Jiang Y, Yu Y, et al. Clinical, cytogenetic, and molecular findings in a fetus with ultrasonic multiple malformations, 4q duplication, and 7q deletion: a case report and literature review. Medicine 2018;97:e13094.
[11] Willatt L, Cox J, Barber J, et al. 3q29 microdeletion syndrome: clinical and molecular characterization of a new syndrome[J]. Am J Hum Genet 2005;77:154–60.
[12] Guo S, Fan XF, Jin JY, et al. A novel proximal 3q29 chromosome microdeletion in a Chinese patient with Chiari malformation type II and Sprengel’s deformity. Mol Cytogenet 2018;11:8.

[13] Citta S, Buono S, Greco D, et al. 3q29 microdeletion syndrome: cognitive and behavioral phenotype in four patients. Am J Med Genet A 2013;161A:3018–22.

[14] Dasouki MJ, Lushingon GH, Hovanes K, et al. The 3q29 microdeletion syndrome: report of three new unrelated patients and in silico “RNA binding” analysis of the 3q29 region. Am J Med Genet A 2011;155A:1654–60.

[15] Digilio MC, Bernardini L, Mingarelli R, et al. 3q29 Microdeletion: a mental retardation disorder unassociated with a recognizable phenotype in two mother-daughter pairs. Am J Med Genet A 2009;149A:1777–81.

[16] Li F, Lisi EC, Wohler ES, et al. 3q29 interstitial microdeletion syndrome: an inherited case associated with cardiac defect and normal cognition. Eur J Med Genet 2009;52:349–52.

[17] Ballif BC, Theisen A, Coppinger J, et al. Expanding the clinical phenotype of the 3q29 microdeletion syndrome and characterization of the reciprocal microduplication. Mol Cytogenet 2008;1:8.

[18] Montfort S, Rosello M, Orellana C, et al. Detection of known and novel genomic rearrangements by array based comparative genomic hybridization; deletion of ZNF533 and duplication of CHARGE syndrome genes. J Med Genet 2008;45:432–7.

[19] Huang Y, Huang J, Huang Y, et al. TFRC promotes epithelial ovarian cancer cell proliferation and metastasis via up-regulation of AXIN2 expression. Am J Cancer Res 2020;10:131–47.

[20] Ciobanu LG, Sachdev PS, Trollor JN, et al. Downregulated transferrin receptor in the blood predicts recurrent MDD in the elderly cohort: a fuzzy forests approach. J Affect Disord 2020;267:42–8.

[21] Sethi MK, Buettner FF, Ashikov A, et al. Molecular cloning of a xylosyltransferase that transfers the second xylose to O-glucosylated epidermal growth factor repeats of notch. J Biol Chem 2012;287:2739–48.

[22] Pandey A, Li-Kroeger D, Sethi MK, et al. Sensitized genetic backgrounds reveal differential roles for EGF repeat xylosyltransferases in Drosophila Notch signaling. Glycobiology 2018;28:849–59.

[23] Sullivan KD, Nakagawa A, Xue D, et al. Human ACAP2 is a homolog of C. elegans CNT-1 that promotes apoptosis in cancer cells. Cell Cycle 2015;14:1771–8.

[24] Barozzi C, Galletti M, Tomasi L, et al. A combined targeted and whole exome sequencing approach identified novel candidate genes involved in heritable pulmonary arterial hypertension. Sci Rep 2019;9:753.